Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03675724
Other study ID # 18-007332
Secondary ID
Status Enrolling by invitation
Phase Phase 2
First received
Last updated
Start date November 15, 2018
Est. completion date October 2024

Study information

Verified date February 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone resorption in elderly adults.


Description:

To the researchers' knowledge, there are no published studies utilizing Fisetin in alteration of frailty markers. Several studies involve use of Fisetin for its anti-oxidative and anti-apoptotic effects in animal models. Fisetin may reduce oxidative stress, alleviate hyperglycemia, and improve kidney function. No one has evaluated the biologic markers of inflammation and frailty in older adults. The researchers plan to evaluate markers of frailty and markers of inflammation, insulin resistance, and bone resorption while maintaining bone formation in older adults.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 40
Est. completion date October 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria • Age = 70 years Exclusion Criteria - Unable or unwilling to give informed consent - Pregnant - Body weight >150 kg or body mass index (BMI) > 50 - QTc>450 msec - Total bilirubin >2X upper limit of normal - Inability to tolerate oral medication - Abnormality in any of the screening laboratory studies (see below) - Human immunodeficiency virus infection - Known active hepatitis B or C infection - Invasive fungal or viral infection - Known hypersensitivity or allergy to fisetin - Uncontrolled pleural/pericardial effusions or ascites - New/active invasive cancer except non-melanoma skin cancers - Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic. - Strong inhibitors of CYP3A4. See Appendices 1-3. - Tyrosine kinase inhibitor therapy - Known hypersensitivity or allergy to fisetin - Subjects on quinolone antibiotic therapy for treatment or for prevention of infections within 10 days. - Subjects taking H2-antagonists and unwilling to discontinue therapy for 1 week before and 2 weeks following enrollment. - Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax - Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy - Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin,erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin - Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold therapy 2 days prior to and during the 2-day Fisetin dosing - Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of Fisetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, , eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole - In order to ensure vitamin D sufficiency, we will also exclude subjects with serum 25-hydroxyvitamin D levels of < 20 ng/ml. - Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial. Behavioral Modification - Participants will be educated about the risk of excessive caffeine usage. Participants will be encouraged to reduce use by 50% prior to and during the 2-day drug dosing period. Due to drug-drug interaction, subjects may not clear the caffeine from their system properly/as usual.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Fisetin
Flavonoid Family
Drug:
Placebo oral capsule
Placebo

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decrease in blood inflammation markers Percent decrease in blood inflammation markers Seven Days
See also
  Status Clinical Trial Phase
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Completed NCT03271112 - Frailty Prevention in Elders From Reunion Island N/A
Recruiting NCT03141866 - Seated Physical Activity in Ageing N/A
Completed NCT03180606 - Enhanced Primary Care for Elderly
Recruiting NCT05940779 - Relationship Between the Risk of Falls and Frailty, and the Effect of a Physical Exercise Program on These Conditions in the Elderly: a Randomized Crossover Clinical Trial. N/A
Active, not recruiting NCT05961319 - Smart Home Technologies for Assessing and Monitoring Frailty in Older Adults
Recruiting NCT04518423 - Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People
Completed NCT03883425 - Frailty and Complexity Among Home Service Recipients
Recruiting NCT03657940 - Impact of a Multicomponent Exercise Program on Functional Capacity in Frail Aged Participants With Cognitive Decline N/A
Withdrawn NCT03176030 - Fortified Foods in Older Inpatients
Completed NCT03724461 - Effects of Resistance Training With High vs. Light-moderate Loads on Muscle-tendon Function in the Elderly N/A
Completed NCT04615533 - Validity Reliability of FrailBESTest in Older Adults
Recruiting NCT04238494 - Muscle Multi-parametric NMR Imaging Development in Aged People With Sarcopenia or Frailty Syndrome; CLINical Study N/A
Active, not recruiting NCT06079762 - AGE SELF CARE: Promoting Healthy Aging Through a Group Visit Program N/A
Not yet recruiting NCT06019390 - eHealth for Screening Health Risks in Home-Based Older Adults: A Prospective Study N/A
Recruiting NCT03534765 - Frailty and Sarcopenia Outcomes in Emergency General Surgery
Active, not recruiting NCT03721471 - Outcome of Very Old Patients Admitted for Elective Major Surgery, the Effect of Frailty
Completed NCT03688932 - Effects of WBV Associated With IMT on Functionality N/A
Completed NCT03689322 - Effects of WBV Associated With IMT on Inflammatory Markers, Body Composition, Muscle Strength and Thickness N/A
Recruiting NCT03068299 - Effects of Music and Dance on Cognition, Frailty, and Burden in Elderly Caregivers Living in Rural Communities N/A

External Links